Sergey Tselmin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergey Tselmin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
G. Müller
Center for Evidence-Based Healthcare, Medizinische Fakultät Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany
5 shared publications- Ulrich Julius
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
5 shared publications - Stefan Richard Bornstein
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
4 shared publications U. Julius
Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
4 shared publications- Bernd Hohenstein
Department of Internal Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität, Dresden, Germany
3 shared publications S. Fischer
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
2 shared publications
Latest Publications
- 14 July 2022
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 54 (08) , 514-521
COVID-19 and Lipid Disorders
An elevated cholesterol concentration has been suspected to increase the susceptibility for SARS-COV-2 infection. Cholesterol plays a central role in the mechanisms of the SARS-COV-2 infection. In contrast, higher HDL-cholesterol levels seem to be protective. During COVID-19 disease, LDL-cholesterol and HDL-cholesterol appear to be decreased. On the other hand, triglycerides (also in different lipoprotein fractions) were elevated. Lipoprotein(a) may increase during this disease and is most probably responsible for thromboembolic events. This lipoprotein can induce a progression of atherosclerotic lesion formation. The same is suspected for the SARS-COV-2 infection itself. COVID-19 patients are at increased risk of incident cardiovascular diseases, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disorders. An ongoing lipid-lowering therapy, including lipoprotein apheresis, is recommended to be continued during the COVID-19 disease, though the impact of lipid-lowering drugs or the extracorporeal therapy on prognosis should be studied in further investigations.
- 14 July 2022
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 54 (08) , 514-521
COVID-19 and Lipid Disorders
An elevated cholesterol concentration has been suspected to increase the susceptibility for SARS-COV-2 infection. Cholesterol plays a central role in the mechanisms of the SARS-COV-2 infection. In contrast, higher HDL-cholesterol levels seem to be protective. During COVID-19 disease, LDL-cholesterol and HDL-cholesterol appear to be decreased. On the other hand, triglycerides (also in different lipoprotein fractions) were elevated. Lipoprotein(a) may increase during this disease and is most probably responsible for thromboembolic events. This lipoprotein can induce a progression of atherosclerotic lesion formation. The same is suspected for the SARS-COV-2 infection itself. COVID-19 patients are at increased risk of incident cardiovascular diseases, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disorders. An ongoing lipid-lowering therapy, including lipoprotein apheresis, is recommended to be continued during the COVID-19 disease, though the impact of lipid-lowering drugs or the extracorporeal therapy on prognosis should be studied in further investigations.
- Open Access
- 16 July 2020
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 7 (3) , 25
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of the LA therapy. We compared personal and lab data in two groups: CVEx/0 (n 60) with no new events during LA therapy, CVEx/1+ (n 48) with at least one new event. Patients of Group CVEx/1+ were about 5 years older when they had started the extracorporeal therapy, and they experienced more CVEs prior to that timepoint. There was a positive correlation between the number of CVEs before and during LA therapy. No differences were seen with respect to lipid concentrations, even after a correction of LDL-C concentrations for the LDL-C transported with Lp(a) particles. LA sessions effectively reduced both LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower than those measured initially. It appeared difficult to reach the target values for LDL-C published in the ESC/EAS Guideline in 2019, although all patients were maximally treated including drugs when tolerated. In conclusion, it will be important to initiate an LA therapy earlier, at least after a second CVE and at a younger age.
- 16 July 2020
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 7 (3) , 25
Open AccessWhy Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of the LA therapy. We compared personal and lab data in two groups: CVEx/0 (n 60) with no new events during LA therapy, CVEx/1+ (n 48) with at least one new event. Patients of Group CVEx/1+ were about 5 years older when they had started the extracorporeal therapy, and they experienced more CVEs prior to that timepoint. There was a positive correlation between the number of CVEs before and during LA therapy. No differences were seen with respect to lipid concentrations, even after a correction of LDL-C concentrations for the LDL-C transported with Lp(a) particles. LA sessions effectively reduced both LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower than those measured initially. It appeared difficult to reach the target values for LDL-C published in the ESC/EAS Guideline in 2019, although all patients were maximally treated including drugs when tolerated. In conclusion, it will be important to initiate an LA therapy earlier, at least after a second CVE and at a younger age.
- 1 December 2019
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 40, 38-43
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis
- 1 December 2019
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 40, 38-43
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis
- Open Access
- 9 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 8,p. 74-78
LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
АФЕРЕЗ ЛИПОПРОТЕИДОВ: ВЧЕРА, СЕГОДНЯ, ЗАВТРА
- 9 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 8,p. 74-78
Open AccessLIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
АФЕРЕЗ ЛИПОПРОТЕИДОВ: ВЧЕРА, СЕГОДНЯ, ЗАВТРА
- 12 December 2017
- Published by Springer Nature in CardioVasc
- Vol. 17 (6) , 44-46
„Nebenwirkung“ wandelt sich in einen Vorteil
- 12 December 2017
- Published by Springer Nature in CardioVasc
- Vol. 17 (6) , 44-46
„Nebenwirkung“ wandelt sich in einen Vorteil
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 278-282
Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 278-282
Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 246-252
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 246-252
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 209-216
Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 209-216
Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia
- 1 May 2015
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 257-262
An elevated lipoprotein(a) plasma level as a cardiovascular risk factor
- 1 May 2015
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 257-262
An elevated lipoprotein(a) plasma level as a cardiovascular risk factor
- 1 January 2013
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 14 (1) , 123-128
Homocysteine in lipoprotein apheresis patients – Retrospective data analysis in apheresis center of a university hospital
- 1 January 2013
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 14 (1) , 123-128
Homocysteine in lipoprotein apheresis patients – Retrospective data analysis in apheresis center of a university hospital